Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1Recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 9Gastrointestinal 2Sarcoma 1NET 1Head & Neck 1Gynecologic 1Endocrine 1Dermatologic 1

Conditions

Neuroendocrine Tumors 111Gastro-enteropancreatic neuroendocrine tumor 19Carcinoma, Neuroendocrine 12Stomach Neoplasms 11Pancreatic Neoplasms 10Neoplasms 10Breast Neoplasms 10Pheochromocytoma 9Carcinoid Tumor 9Prostatic Neoplasms 8Paraganglioma 8Neoplasm Metastasis 8Carcinoma, Hepatocellular 8Adenoma, Islet Cell 8Thyroid Neoplasms 7Sarcoma 7Gastrointestinal Neoplasms 7Esophageal Neoplasms 7Colorectal Neoplasms 7Lung Neoplasms 6Rectal Neoplasms 5Ovarian Neoplasms 5Neuroblastoma 5Melanoma 5Liver Neoplasms 5Colonic Neoplasms 5Anus Neoplasms 5Uterine Cervical Neoplasms 4Gastrointestinal Stromal Tumors 4Cholangiocarcinoma 4

Interventions

repotrectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Bronchial Neoplasms × NET × Clear all
NCT03093116 2026-05-27

TRIDENT-1

Turning Point Therapeutics, Inc.

Phase 1/2 Recruiting
500 enrolled 2 FDA
EndocrineGastrointestinalHead & NeckNETSarcomaThoracic

Adenocarcinoma, Bronchial Neoplasms, Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Colonic Diseases, Colonic Neoplasms, Digestive System Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Sarcoma, Thoracic Neoplasms, Thyroid Diseases, Thyroid Neoplasms, Neuroectodermal Tumors, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡